| Previous close | 99.90 |
| Open | 98.10 |
| Bid | 100.80 x 0 |
| Ask | 101.60 x 0 |
| Day's range | 98.00 - 103.00 |
| 52-week range | 35.01 - 183.00 |
| Volume | 774,238 |
| Avg. volume | 2,281,559 |
| Market cap | 185.709M |
| Beta (5Y monthly) | 2.84 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -19.20 |
| Earnings date | 24 May 2021 - 28 May 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 400.00 |
- Business Wire
4D pharma Completes Enrollment of Part A of the Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma and Provides Program Update
4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces the completion of its target enrollment of 30 patients for Part A of its Phase I/II clinical trial of MRx-4DP0004 in patients with partly-controlled asthma. Following the completion of enrollment of Part A, 4D pharma expects to announce topline results from these patients in the second half of 2021.
- Business Wire
4D pharma Presents Additional Positive Results of Phase II Study of Blautix® for the Treatment of Irritable Bowel Syndrome
4D pharma plc (AIM: DDDD; NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces additional positive data from its completed Phase II trial of LBP Blautix® in subjects with irritable bowel syndrome with constipation (IBS-C) or with diarrhea (IBS-D).
- Business Wire
4D pharma to Present Additional Data from Phase II Study of Blautix for the Treatment of Irritable Bowel Syndrome at Digestive Disease Week (DDW) 2021
4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announced that it will present data from its Phase II study of single strain LBP Blautix® in patients with irritable bowel syndrome (IBS) subtypes IBS-C and IBS-D in a poster session at Digestive Disease Week (DDW) 2021, taking place virtually May 21-23, 2021.
